Stereotactic radiotherapy of hepatocellular carcinoma: Preliminary results

Technology in Cancer Research and Treatment

Volumn 9, Issue 5, 2010, Pages 479-487

  Louis, C ^a,b   Dewas, S ^b   Mirabel, Xavier ^b,c   Lacornerie, T ^b   Adenis, A ^c   Bonodeau, F ^d   Lartigau, E ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b O Lambret Center   (France)

^c Oscar Lambret Centre   (France)

^d Medical Department   (France)

Author keywords

Hepatocellular carcinoma; Stereotactic radiation therapy

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CYBERKNIFE; DIARRHEA; DISEASE SEVERITY; DISTANT METASTASIS; DYSPHAGIA; EPIGASTRIC PAIN; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTRITIS; GASTRODUODENAL ULCER; HEMATOMA; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; MALE; NAUSEA; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RATING SCALE; STEREOTACTIC RADIOSURGERY; VOMITING;

EID: 78049243940     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303461000900506     Document Type: Article

References (42)

1. Varela, M., Sala, M., Llovet, J. M., Bruix, J. Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 29, 99-104 (2003). (Pubitemid 36519391)
2. Davis, G. L., Dempster, J., Meler, J. D., Orr, D. W., Walberg, M. W., Brown, B., Berger, B. D., O'Connor, J. K., Goldstein, R. M. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) 21, 266-280 (2008).
3. Garcia-Tsao, G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 120, 726-748 (2001).
4. Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., Colombo, M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43, 1303-1310 (2006).
5. Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., Rodes, J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35, 421-430 (2001).
6. Lau, W. Y., Lai, E. C. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7, 237-257 (2008).
7. Bismuth, H., Chiche, L., Adam, R., Castaing, D., Diamond, T., Dennison, A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218, 145-151 (1993). (Pubitemid 23229140)
8. Orlando, A., Cottone, M., Virdone, R., Parisi, P., Sciarrino, E., Maringhini, A., Caltagirone, M., Simonetti, R. G., Pagliaro, L. Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group. Scand J Gastroenterol 32, 598-603 (1997).
9. Matsui, O., Kadoya, M., Yoshikawa, J., Gabata, T., Arai, K., Demachi, H., Miyayama, S., Takashima, T., Unoura, M., Kogayashi, K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188, 79-83 (1993).
10. Horigome, H., Nomura, T., Nakao, H., Fujino, N., Murasaki, G., Kanematsu, T., Joh, T., Ohara, H., Itoh, M. Percutaneous radiofrequency ablation therapy using a clustered electrode for malignant liver tumors. J Clin Gastroenterol 32, 418-422 (2001). (Pubitemid 32378275)
11. Cheng, J. C., Chuang, V. P., Cheng, S. H., Huang, A. T., Lin, Y. M., Cheng, T. I., Yang, P. S., You, D. L., Jian, J. J., Tsai, S. Y., Sung, J. L., Horng, C. F. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 47, 435-442 2000).
12. Friedland, J. L., Freeman, D. E., Materson-McGary, M. E., spelberg, D. M. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res treat 8, 387-392 (2009).
13. Kunos, C., von Gruenigen, V., Waggoner, S., Brindle, J., Zhang, Y., Myers, B., Funkhouser, G., Wessels, B., Einstein, D. Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. Technol Cancer Res Treat 7, 375-380 (2008).
14. Prevost, J. B., Voet, P., Hoogeman, M., Praag, J., Levendag, P., Nuyttens, J. J. Four-dimensional Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer: A comparative planning study. Technol Cancer Res treat 7, 27-33 (2008).
15. Blomgren, H., Lax, I., Goranson, H., Kraepelien, T., Nilsson, B., Naslund, I., Svanstrom, R., Tilikidis, A. Radiosurgery for Tumors in the Body: Clinical Experience Using a New Method. J. Radiosurgery 1, 63-74 (1998).
16. Blomgren, H., Lax, I., Naslund, I., Svanstrom, R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34, 861-870 (1995).
17. Herfarth, K. K., Debus, J., Lohr, F., Bahner, M. L., Rhein, B., Fritz, P., Hoss, A., Schlegel, W., Wannenmacher, M. F. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19, 164-170 (2001).
18. Choi, B. O., Jang, H. S., Kang, K. M., Lee, S. W., Kang, Y. N., Chai, G. Y., Choi, I. B. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 36, 154-158 2006).
19. Choi, B. O., Choi, I. B., Jang, H. S., Kang, Y. N., Jang, J. S., Bae, S. H., Yoon, S. K., Chai, G. Y., Kang, K. M. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 8, 351 (2008).
20. Mendez Romero, A., Wunderink, W., Hussain, S. M., De Pooter, J. A., Heijmen, B. J., Nowak, P. C., Nuyttens, J. J., Brandwijk, R. P., Verhoef, C., Ijzermans, J. N., Levendag, P. C. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45, 831-837 (2006).
21. Tse, R. V., Hawkins, M., Lockwood, G., Kim, J. J., Cummings, B., Knox, J., Sherman, M., Dawson, L. A. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26, 657-664 2008). (Pubitemid 351264363)
22. Wulf, J., Guckenberger, M., Haedinger, U., Oppitz, U., Mueller, G., Baier, K., Flentje, M. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45, 838-847 (2006).
23. Yang, Z. X., Wang, D., Wang, G., Zhang, Q. H., Liu, J. M., Peng, P., Liu, X. H. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol (2009).
24. Lin, C. S., Jen, Y. M., Chiu, S. Y., Hwang, J. M., Chao, H. L., Lin, H. Y., Shum, W. Y. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 36, 212-217 2006).
25. Llovet, J. M., Beaugrand, M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 Suppl 1, S136-149 (2003).
26. Kojiro, M. The evolution of pathologic features of hepatocellular carcinoma. In: Tabor E (ed) Viruses and liver cancer, edn. Elsevier, Amsterdam, pp (2002).
27. Timmerman, R. D. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Seminars in Radiation Oncology. vol 18, n 4, 2008.
28. Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., Bruix, J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616-623 (2009).
29. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 205-216 (2000).
30. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf].
31. Llovet, J. M., Burroughs, A., Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
32. Llovet, J. M., Ricci, S., Mazzafero, V., Hilgard, P., Raoul, J., Zeuzem, S. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial. J Clin Oncol 25, LBA1 (2007).
33. Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23, 6657-6663 (2005).
34. Siegel, A. B., Cohen E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., Christos, P., Mazumdar, M., Popa, E., Brown R. S., Jr., Rafii, S., Schwartz, J. D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26, 2992-2998 (2008).
35. Zhu, A. X., Stuart, K., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K., Fuchs, C. S., Ryan, D. P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110, 581-589 (2007).
36. Mohnike, K., Wieners, G., Pech, M., Seidensticker, M., Ruhl, R., Lopez-Haenninen, E., Ricke, J. Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. Dig Dis 27, 170-174 (2009).
37. Hsieh, C. H., Jeng, K. S., Lin, C. C., Chen, C. K., Liu, C. Y., Lin, C. P., Tai, H. C., Wang, C. H., Shueng, P. W., Chen, Y. J. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 29, 65-71 (2009).
38. Czito, B. G., Bendell, J. C., Willett, C. G., Morse, M. A., Blobe, G. C., Tyler, D. S., Thomas, J., Ludwig, K. A., Mantyh, C. R., Ashton, J., Yu, D., Hurwitz, H. I. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68, 472-478 (2007).
39. Rossi, A., Maione, P., Colantuoni, G., Ferrara, C., Rossi, E., Guerriero, C., Nicolella, D., Falanga, M., Palazzolo, G., Gridelli, C. Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol 6, 91-102 (2009).
40. Elser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., Wilkie, D., Petrenciuc, O., Chen, E. X. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25, 3766-3773 (2007).
41. Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H. R., Cupissol, D., Peyrade, F., Benasso, M., Vynnychenko, I., De Raucourt, D., Bokemeyer, C., Schueler, A., Amellal, N., Hitt, R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359, 1116-1127 (2008).
42. Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., Marrano, P., da Cunha Santos, G., Lagarde, A., Richardson, F., Seymour, L., Whitehead, M., Ding, K., Pater, J., Shepherd, F. A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353, 133-144 (2005).